



Suggested Formula	Gabapentin 6%, Ketamine Hydrochloride 9.2%, Ketoprofen 8% Topical Cream (Emulsion, 100 g)	FIN	F 004 550v3
-------------------	---	-----	-------------

**Note:** Ketamine Hydrochloride 9.2% is equivalent to Ketamine 8%.

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Gabapentin, USP	6.000	g				
Ketamine Hydrochloride, USP	9.200	g				
Ketoprofen, USP	8.000	g				
Pentylene Glycol	5.0	mL				
Ethoxy Diglycol	7.0	mL				
Medisca VersaPro™ Cream Base	64.75	g				

## SPECIAL PREPARATORY CONSIDERATIONS

### Ingredient-Specific Information

**Controlled substance** (adhere to proper handling and documentation procedures)

*Ketamine Hydrochloride*

**Light sensitive** (protect from light whenever possible):

*Ketamine Hydrochloride, Gabapentin, Ketoprofen*

**Hygroscopic** (protect from moisture whenever possible):

*Ethoxy Diglycol, Pentylene Glycol*

### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

#### Processing Error /

#### Testing Considerations:

To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

#### Special Instruction:

Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Gabapentin 6%, Ketamine Hydrochloride 9.2%, Ketoprofen 8% Topical Cream (Emulsion, 100 g)	FIN	F 004 550v3
-------------------	---	-----	-------------

### SUGGESTED PREPARATION (for 100 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Gabapentin, USP §	6.000	g			
Ketamine Hydrochloride, USP §	9.200	g			
Ketoprofen, USP §	8.000	g			
Pentylene Glycol §	5.0	mL			
Ethoxy Diglycol §	7.0	mL			
Medisca VersaPro™ Cream Base	64.75	g			

§ Weigh / measure just prior to use.

\* Takes into account increased batch size conversions and density conversions, if required.

#### Preparatory Instruction

- Powder-liquid preparation:**
  - Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:
    - Gabapentin
    - Ketamine Hydrochloride
    - Ketoprofen
  - Combine and mix the following ingredients together to form a homogeneous liquid-like solution:
    - Ethoxy Diglycol
    - Pentylene Glycol
  - Levigate the fine, homogeneous powder blend (Step 1A) with the homogeneous liquid-like solution (Step 1B).  
End result: Homogeneous liquid-like dispersion.
- Medium integration:**
  - Incrementally add the homogeneous liquid-like dispersion (Step 1C) to the VersaPro™ Cream Base.  
Specifications: Continuously mix, using high-shear mixing techniques.  
End result: Homogeneous cream-like dispersion.



Suggested Formula	Gabapentin 6%, Ketamine Hydrochloride 9.2%, Ketoprofen 8% Topical Cream (Emulsion, 100 g)	FIN	F 004 550v3
-------------------	---	-----	-------------

3.	<b><u>Product transfer:</u></b> Transfer the final product into the specified dispensing container (see “Packaging requirements”).
----	---

### SUGGESTED PRESENTATION

Estimated Beyond-Use Date	30 days, as per USP.	Packaging Requirements	- Tightly closed, light-resistant ointment tube/jar. - To be administered with a metered-dose measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	7	Keep in a dry place.
	2	Keep out of reach of children.	8	Cap tightly after use.
	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	9	For external use only.
	4	Protect from light.	10	May impair mental and/or physical ability. Use care when operating a car or machinery.
	5	Keep at room temperature (20°C – 23°C).	11	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	6	Controlled substance. Dangerous unless used as directed.	12	May produce psychological and/or physical dependence.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.  <b>IMPORTANT: DRUG-DRUG INTERACTION EXISTS BETWEEN GABAPENTIN AND KETAMINE HYDROCHLORIDE. TO BE DISPENSED AND ADMINISTERED ONLY UNDER THE CLOSE SUPERVISION OF THE PRESCRIBING PHYSICIAN.</b>			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.  <b>IMPORTANT:</b> The quantity of API administered is directly dependent on the quantity of product applied.			

### REFERENCES

1.	Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 235.
2.	Neurontin. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2010</i> . 1551.
3.	Apo-Keto-E. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2010</i> . 211.



Suggested Formula	Gabapentin 6%, Ketamine Hydrochloride 9.2%, Ketoprofen 8% Topical Cream (Emulsion, 100 g)	FIN	F 004 550v3
-------------------	---	-----	-------------

4.	Ketamine Hydrochloride Injection. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2010</i> . 1219.
5.	Gabapentin. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 482.
6.	Ketoprofen. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 73.
7.	Ketamine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 1787.
8.	Ketoprofen (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #5305.
9.	Ketamine (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #5295.
10.	Gabapentin (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #4319.
11.	Gabapentin. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 254.
12.	Ketoprofen. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 315.
13.	Ketamine Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 313.
14.	Gabapentin (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2462.
15.	Ketoprofen (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2739.
16.	Ketamine Hydrochloride (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2736.
17.	Gabapentin. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1561.
18.	Ketoprofen. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 423.
19.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

**DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.**